Single peptide Vial strength 5 mg
CJC-1295 NO DAC5 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
CJC-1295 NO DAC, explained simply
A shorter-acting GHRH analogue than the DAC version, also known as Modified GRF 1-29.
Research area
Pulsatile growth hormone release
How it works
Interacts with pituitary GHRH receptors and stimulates GH release in pulses.
Why it matters
It is investigated for effects on the GH/IGF-1 axis and body composition.
What has been observed
The data primarily concern hormonal changes; recovery and body composition remain research questions.
Effects and points to consider
Its duration and activity profile differ from CJC-1295 DAC. The two names should not be used interchangeably.
01 / Vial strength 5 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 5 mg CJC-1295 NO DAC |
|---|---|
| Final volume | 3 mL |
| Concentration | 1.67 mg/mL |
| One U-100 unit | 16.67 mcg in 0.01 mL |
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) |
| Weeks 5–6 | 200 mcg | 12 units (0.12 mL) |
| Weeks 7–12 | 250–300 mcg | 15–18 units (0.15–0.18 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.